Effect of treatment on the immunological status of women with advanced breast cancer.
An immunological profile has been serially studied in 72 patients with advanced breast cancer during the course of a randomized trial of chemotherapy and hormonal manipulation. DNCB+ patients were more likely to respond to either therapy, but no other test was predictive of response. In the follow-up period all chemotherapy patients had a reduction in white-cell count which was significantly greater in those responding to treatment. None of the other tests (phytohaemagglutinin response, immunoglobulins G, A and M, or Mantoux test) demonstrated changes that could be related to treatment or response, but there was a gradual unexplained fall in IgM levels in all groups the study progressed. It is concluded that the chemotherapeutic regimen (cyclophosphamide, vincristine, adriamycin and 5-fluorouracil) is relatively non-immunosuppressive, and that hormonal therapy (oophorectomy, tamoxifen or androgens) had no detectable effect on the immune response.
D000917:Antibody Formation; D000941:Antigens / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D004137:Dinitrochlorobenzene / Q000276:immunology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000502:physiology; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007165:Immunosuppression Therapy; D008214:Lymphocytes / Q000276:immunology; D008593:Menopause; D009362:Neoplasm Metastasis; D014374:Tuberculin Test
D000941:Antigens; D000970:Antineoplastic Agents; D004137:Dinitrochlorobenzene; D012739:Gonadal Steroid Hormones; D007136:Immunoglobulins